{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Triple+Intrathecal+Therapy+%28MTX%2C+Cytarabine%2C+Hydrocortisone%29", "query": { "intervention": "Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Triple+Intrathecal+Therapy+%28MTX%2C+Cytarabine%2C+Hydrocortisone%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-09T01:24:47.125Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01861002", "title": "A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoblastic Leukemia, Acute, Childhood", "Myelogenous Leukemia, Acute, Childhood" ], "interventions": [ { "name": "Azacytidine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Intrathecal (IT) Cytarabine", "type": "DRUG" }, { "name": "Intrathecal Methotrexate (IT MTX)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 15, "start_date": "2013-05-22", "completion_date": "2014-07-28", "has_results": true, "last_update_posted_date": "2021-06-09", "last_synced_at": "2026-10-09T01:24:47.125Z", "location_count": 19, "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 16 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01861002" }, { "nct_id": "NCT00002970", "title": "506U78 in Treating Patients With Refractory Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Lymphoblastic Lymphoma", "T-cell Childhood Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "nelarabine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 148, "start_date": "1997-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-02", "last_synced_at": "2026-10-09T01:24:47.125Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002970" }, { "nct_id": "NCT03913559", "title": "Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Inotuzumab ozogamicin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 5, "start_date": "2019-05-14", "completion_date": "2025-09-15", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-10-09T01:24:47.125Z", "location_count": 2, "location_summary": "San Diego, California • Memphis, Tennessee", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03913559" }, { "nct_id": "NCT00096135", "title": "Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "pegaspargase", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Months", "maximum_age": "29 Years", "sex": "ALL", "summary": "18 Months to 29 Years" }, "enrollment_count": 168, "start_date": "2004-11", "completion_date": null, "has_results": true, "last_update_posted_date": "2017-03-21", "last_synced_at": "2026-10-09T01:24:47.125Z", "location_count": 135, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 116 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096135" }, { "nct_id": "NCT06289673", "title": "Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Lymphoblastic Lymphoma", "Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 850, "start_date": "2024-12-26", "completion_date": "2039-05", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-09T01:24:47.125Z", "location_count": 5, "location_summary": "San Diego, California • Baton Rouge, Louisiana • Charlotte, North Carolina + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Tulsa", "state": "Oklahoma" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06289673" }, { "nct_id": "NCT06533748", "title": "Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Inotuzumab", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "IT MHA", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "6-Mercaptopurine", "type": "DRUG" }, { "name": "Calaspargase", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 128, "start_date": "2025-01-23", "completion_date": "2034-05", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-09T01:24:47.125Z", "location_count": 3, "location_summary": "Charlotte, North Carolina • Tulsa, Oklahoma • Memphis, Tennessee", "locations": [ { "city": "Charlotte", "state": "North Carolina" }, { "city": "Tulsa", "state": "Oklahoma" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06533748" }, { "nct_id": "NCT00002798", "title": "Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Childhood Acute Erythroleukemia (M6)", "Childhood Acute Megakaryocytic Leukemia (M7)", "Childhood Acute Monoblastic Leukemia (M5a)", "Childhood Acute Monocytic Leukemia (M5b)", "Childhood Acute Myeloblastic Leukemia With Maturation (M2)", "Childhood Acute Myeloblastic Leukemia Without Maturation (M1)", "Childhood Acute Myelomonocytic Leukemia (M4)", "Childhood Myelodysplastic Syndromes", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndromes", "Refractory Anemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Refractory Anemia With Ringed Sideroblasts", "Secondary Myelodysplastic Syndromes", "Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies" ], "interventions": [ { "name": "asparaginase", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "idarubicin", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "thioguanine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 880, "start_date": "1996-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-10-09T01:24:47.125Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002798" }, { "nct_id": "NCT03792256", "title": "Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Lymphocytic", "Lymphoblastic Lymphoma", "T-cell Lymphoma", "T-cell Leukemia", "Recurrent Disease", "Acute Leukemia" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "31 Years", "sex": "ALL", "summary": "12 Months to 31 Years" }, "enrollment_count": 12, "start_date": "2019-04-11", "completion_date": "2023-09-30", "has_results": true, "last_update_posted_date": "2025-03-21", "last_synced_at": "2026-10-09T01:24:47.125Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Loma Linda, California • Orange, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Loma Linda", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03792256" }, { "nct_id": "NCT06390319", "title": "Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T-cell Acute Lymphoblastic Leukemia", "T-cell Lymphoma", "Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Calaspargase pegol", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 100, "start_date": "2024-12-27", "completion_date": "2033-12", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-09T01:24:47.125Z", "location_count": 4, "location_summary": "San Diego, California • Charlotte, North Carolina • Tulsa, Oklahoma + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Tulsa", "state": "Oklahoma" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06390319" }, { "nct_id": "NCT00928200", "title": "Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Acute Lymphoblastic Leukemia", "Allergy to PEG e.Coli Asparaginase", "Allergy to Native e.Coli Asparaginase" ], "interventions": [ { "name": "Erwinase", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Triple Intrathecal Therapy", "type": "DRUG" }, { "name": "Dexrazoxane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 1, "start_date": "2009-04-13", "completion_date": "2010-06-04", "has_results": true, "last_update_posted_date": "2019-02-19", "last_synced_at": "2026-10-09T01:24:47.125Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00928200" } ] }